Drugs / Lexatumumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00428272 | Dec 2006 → Apr 2011 | Ewing sarcoma, neuroblastoma, osteosarcoma, rhabdomyosarcoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lexatumumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00428272 ↗ |
| Known as | ETR2-ST01 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743036 ↗ |
| Known as | HGS-1018 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743036 ↗ |
| Known as | HGS-ETR2 | “A Phase I Trial of Monoclonal Antibody HGS-ETR2 (Lexatumumab) With or Without Interferon Gamma in Patients With Refractory Pediatric Solid Tumors” NCT00428272 ↗ |
| Action | Activate | “Tumor necrosis factor receptor superfamily member 10B agonist” CHEMBL1743036 ↗ |
| Modality | Monoclonal antibody | “Lexatumumab is an agonistic, fully human monoclonal antibody against tumor necrosis factor-related apoptosis-inducing ligand receptor 2” PMID 23071222 ↗ Oct 2012 |
| Target | TNFRSF10B | “Tumor necrosis factor receptor superfamily member 10B agonist” CHEMBL1743036 ↗ |